AUPH - Aurinia Pharmaceuticals Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$16.00
DETAILS
HIGH:
$16.00
LOW:
$16.00
MEDIAN:
$16.00
CONSENSUS:
$16.00
UPSIDE:
5.12%
About Aurinia Pharmaceuticals Inc. (https://www.auriniapharma.com)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Peter S. Greenleaf | Consultant | 1970 | $1,700,080 USD |
| Matthew Maxwell Donley | Chief Operations Officer | 1969 | $933,951 USD |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 1982 | $923,480 USD |
| Joseph Miller | Chief Financial Officer | 1974 | $866,870 USD |
| Michael S. Hearne | Chief Financial Officer | 1963 | $866,870 USD |
| Gregory F. Keenan | Senior VP & Chief Medical Officer | 1962 | $779,114 USD |
| Andrea Levin Christopher | Executive Director of Corporate Communications & Investor Relations | – | – |
| Eric Victory | Vice President of Corporate Development | – | – |
| Kevin C. Tang | Chairman & CEO | 1967 | – |
| Lucy Shieh | Vice President of Human Resources & Operations | – | – |
| Michael Gammons | Vice President & Chief Information Officer | – | – |
| Premchandran Ramiya | Senior Vice President of Manufacturing & Supply Chain | 1961 | – |
| Richard Lewis | Vice President of Sales | – | – |
| Ryan Cole | Chief Operating Officer | 1987 | – |
| Stewart Kroll | Chief Development Officer | 1959 | – |
| Thomas Wei | Chief Scientific Officer | 1976 | – |